A recent publication in the Wall Street Journal discusses a potential receipt of billions of dollars in funding by Intel from the US government with a view to building ‘secure facilities’ for the production of microchips. Specifically, these microchips are intended for usage by the U.S. military and intelligence applications. This development is hinged on the Biden administration’s Chips Act and its main focus is to curtail the U.S. military’s over-dependence on chips sourced from East Asia, particularly Taiwan.
https://www.jdsupra.com/legalnews/will-new-secure-chip-facilities-lead-to-7558041/
The underlying discussion has moved to the concept of the ‘secure enclave’, a term used to refer to the proposed facilities. This discussion has ignited a heated debate among lawmakers, who are examining the possible legal implications and issues that might arise from this development.
The debate around these facilities primarily revolves around the potential for more Qui Tam cases. For those unfamiliar, Qui Tam cases are brought by whistleblowers under the False Claims Act. They play a crucial role in helping the government expose and prosecute instances of fraud. Given that the Chips Act involves substantial taxpayer dollars, any false claim regarding secure microchip production has the potential to give rise to Qui Tam suits.
The expectation that there might be an increase in Qui Tam cases with the implementation of the Chip Act is not far-fetched. While it reflects issues tied to government waste and potential fraud, it also underlines a key strategy for corporate governance and risk management for firms involved in secure microchip production.